Results for tag: "Plasmin Inhibitor"

The Plasmin Inhibitor market is a segment of the Hematological Drugs market, which includes drugs used to treat blood-related diseases. Plasmin Inhibitors are used to treat thromboembolic disorders, such as deep vein thrombosis and pulmonary embolism. These drugs work by inhibiting the activity of plasmin, an enzyme that breaks down fibrin, a protein involved in blood clotting. Plasmin Inhibitors are typically administered intravenously or subcutaneously. The Plasmin Inhibitor market is highly competitive, with a number of companies offering products. Some of the major players in the market include Bayer AG, Pfizer Inc., Sanofi, Bristol-Myers Squibb, and Merck & Co. Show Less Read more